Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib in Anaplastic Thyroid Cancer
NCT04552769Phase 2Completed
- Sponsor
- Stanford University
- Start
- Sep 2020
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abemaciclib in anaplastic thyroid cancer (ATC) and undifferentiated thyroid cancer (ATC), sponsored by Stanford University. Primary endpoint: Overall Response Rate at 8 weeks. Started Sep 2020; status: completed.
02
Drugs
abemaciclib
03
Conditions
anaplastic thyroid cancer (ATC)undifferentiated thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT04552769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04552769.